Conjunctivitis Treatment Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 4.10 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Conjunctivitis Treatment Market Analysis
The conjunctivitis treatment market is expected to register a CAGR of 4.1% over the forecast period.
COVID-19 had a significant impact on the growth of the market during the pandemic period. This is due to the probable frequency of conjunctivitis conditions in coronavirus-infected patients. According to the NCBI article published in August 2021, conjunctivitis can manifest in COVID-19-infected people. Thus, increasing attention toward conjunctivitis during the pandemic had the potential to drive the demand for the market. However, the relaxation of strict lockdowns is expected to increase the patient inflow for conjunctivitis treatment procedures and contribute to the growth of the market studied over the next five years.
The market studied is expected to grow in the forecast period due to the high number of people suffering from conjunctivitis and the easier availability of treatment across the globe. According to the NCBI article published in April 2021, one of the most common ocular disorders among participants was allergic conjunctivitis, with 1.3%. As the disease is very common, hence, treatment is readily available.
Generally, conjunctivitis is self-diagnosable, and there is the least need to undergo any diagnostic test for this disease. Thus the incidence of allergic conjunctivitis is expected to contribute to the market's growth during the forecast period. As per another NIH article published in February 2021, viral and bacterial conjunctivitis are the two common forms of infectious conjunctivitis, with viral infection responsible for up to 80% of all acute conjunctivitis cases and bacterial infection accounting for between 50-75% of cases of infectious conjunctivitis in children. According to the same source, countries like China also have a high incidence of conjunctivitis. Moreover, as per the BMC article published in March 2022, the average annual hemorrhagic conjunctivitis incidence was 3.58/100,000 in mainland China. The rising incidence of hemorrhagic conjunctivitis is expected to drive the demand for conjunctivitis treatment, thereby contributing to market growth.
Hence, owing to the abovementioned factors, the market studied is expected to have steady growth over the forecast period.
Conjunctivitis Treatment Market Trends
This section covers the major market trends shaping the Conjunctivitis Treatment Market according to our research experts:
Allergic Conjunctivitis is Expected to Witness a Steady Growth in the Conjunctivitis Treatment Over the Forecast Period
Allergic conjunctivitis is expected to hold a significant market share over the forecast period. Allergic conjunctivitis is common and causes sudden swelling in the eyelids and ocular itching. People having allergies are more likely to develop allergic conjunctivitis.
As per the Nature article published in April 2022, approximately 10% of the sample population had allergic conjunctivitis. In India, the prevalence of allergic conjunctivitis was 12.22% among those aged between five and 15 years. Also, the NCBI article published in January 2021 mentioned that more than half of the patients report daily symptoms as seasonal or perennial and around 75% consider their symptoms to be severe. The same source also mentioned that there were between 1.2 and 10.6 cases of vernal keratoconjunctivitis per 10,000 individuals in Europe. Such incidence of allergic conjunctivitis is expected to drive the demand for effective treatment, contributing to the growth of the studied segment.
Treatment for acute conjunctivitis includes oral or over-the-counter (OTC) drugs that reduce the release of histamine. Also, anti-inflammatory or anti-inflammation eye drops are available quickly and are found to relieve acute conjunctivitis. Hence, this segment is expected to witness steady growth during the forecast period.
North America is Expected to Dominate the Conjunctivitis Treatment Market Over the Forecast Period
North America is expected to dominate the market, owing to factors such as the easy availability of effective treatment products and high awareness among consumers regarding conjunctivitis in the region. As per the National Library Medicine article published in February 2020, conjunctivitis affects more than 6 million people across the United States every year. The estimated cost for the disease is around USD 377 million to USD 857 million per year. Conjunctivitis is found to be the most frequent disease in the country and affects 15% to 40% of the population, and is seen frequently in spring and summer.
Also, the NCBI article published in January 2021 mentioned that seasonal or perennial allergic conjunctivitis is the most prevalent form of allergic conjunctivitis, with more than 95% of ocular allergy cases in the United States. It is observed in both sexes and affects between 15% and 40% of the population. Such prevalence of conjunctivitis in the United States is expected to drive the demand for effective treatment, thereby contributing to the market's growth during the forecast period.
Due to better healthcare services and the high number of people suffering from conjunctivitis in the United States, the market is expected to hold the largest share shortly.
Also, the high prevalence of conjunctivitis in Canada is expected to contribute to the market's growth over the forecast period. As per the BMC article published in October 2022, it is estimated that 21% of Canadians have dry eyes. Such prevalence of conjunctivitis is expected to contribute to market growth in Canada.
Similarly, the high prevalence of conjunctivitis is expected to contribute to the driving demand for conjunctivitis treatment. As per the World Allergy Organization Journal published in December 2020, 10 medical centers reported a prevalence of allergic rhinoconjunctivitis in children of 11.6%, while adolescents reported 15.4%. Such prevalence of conjunctivitis in Mexico is expected to contribute to the market's growth.
Thus, the factors mentioned above are expected to drive the market's growth during this region's forecast period.
Conjunctivitis Treatment Industry Overview
The conjunctivitis treatment market is moderately consolidated in nature due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international and local companies which hold market shares and are well known, including Allergan, Alembic Pharmaceuticals, Bausch & Lomb Incorporated, Novartis, NicOx SA, and others.
Conjunctivitis Treatment Market Leaders
-
Novartis International AG
-
Bausch & Lomb Incorporated
-
Allergan
-
NicOx S.A.
-
Alembic Pharmaceuticals
*Disclaimer: Major Players sorted in no particular order
Conjunctivitis Treatment Market News
- In May 2022 Santen Pharmaceutical received approval for Verkazia from the National Medical Products Administration (NMPA) in China through its legal entity for treating severe vernal keratoconjunctivitis (VKC) in children and adolescents aged four years and above.
- In March 2022, Visus Therapeutics Inc. announced the launch of the first of two pivotal phases 3 trials (BRIO-I and BRIO-II) for its lead asset, BRIMOCHOL PF, a topical preservative-free ophthalmic solution for treating presbyopia.
Conjunctivitis Treatment Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Number of People Suffering From Conjunctivitis
4.2.2 Easy Availability of the Treatment
4.3 Market Restraints
4.3.1 Availability of Alternative Treatments, such as Home Remedies
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value in USD Million)
5.1 By Disease Type
5.1.1 Allergic Conjunctivitis
5.1.2 Bacterial Conjunctivitis
5.1.3 Viral Conjunctivitis
5.2 By Formulation Type
5.2.1 Ointment
5.2.2 Drops
5.2.3 Drugs
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Novartis AG
6.1.2 Bausch & Lomb Incorporated
6.1.3 Allergan PLC
6.1.4 NicOx SA
6.1.5 Alembic Pharmaceuticals
6.1.6 Sanofi SA
6.1.7 Pfizer Inc.
6.1.8 Sirion Therapeutics Inc
6.1.9 IBA Vision Opthalmics
6.1.10 Santen Pharmaceuticals Co. Ltd
6.1.11 Auven Therapeutics
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Conjunctivitis Treatment Industry Segmentation
As per the scope of the report, conjunctivitis is an irritation or inflammation of the conjunctiva. The Conjunctivitis Treatment market is segmented by Disease Type (Allergic Conjunctivitis, Bacterial Conjunctivitis, Viral Conjunctivitis), Formulation Type (ointment, Drops, and Drugs), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across significant regions globally. The report offers the value (in USD million) for the above segments.
| By Disease Type | |
| Allergic Conjunctivitis | |
| Bacterial Conjunctivitis | |
| Viral Conjunctivitis |
| By Formulation Type | |
| Ointment | |
| Drops | |
| Drugs |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Conjunctivitis Treatment Market Research FAQs
What is the current Conjunctivitis Treatment Market size?
The Conjunctivitis Treatment Market is projected to register a CAGR of 4.10% during the forecast period (2024-2029)
Who are the key players in Conjunctivitis Treatment Market?
Novartis International AG, Bausch & Lomb Incorporated, Allergan, NicOx S.A. and Alembic Pharmaceuticals are the major companies operating in the Conjunctivitis Treatment Market.
Which is the fastest growing region in Conjunctivitis Treatment Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Conjunctivitis Treatment Market?
In 2024, the North America accounts for the largest market share in Conjunctivitis Treatment Market.
What years does this Conjunctivitis Treatment Market cover?
The report covers the Conjunctivitis Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Conjunctivitis Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Urinary Incontinence Treatment Devices Industry Report
Statistics for the 2024 Urinary Incontinence Treatment Devices market share, size and revenue growth rate, created by Mordor Intelligenceā¢ Industry Reports. Urinary Incontinence Treatment Devices analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
Conjunctivitis Treatment Market Report Snapshots
